Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing

Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are effective against lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations. However, cancer cells can develop resistance to these agents with prolonged exposure; in over 50% of cases, this is attributable t...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Mi-Young, Jung, Min Hee, Eo, Eun Young, Kim, Seokjoong, Lee, Sang Hoon, Lee, Yeon Joo, Park, Jong Sun, Cho, Young Jae, Chung, Jin Haeng, Kim, Cheol Hyeon, Il Yoon, Ho, Lee, Jae Ho, Lee, Choon-Taek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482658/
https://www.ncbi.nlm.nih.gov/pubmed/28422737
http://dx.doi.org/10.18632/oncotarget.16752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482658/
https://www.ncbi.nlm.nih.gov/pubmed/28422737
http://dx.doi.org/10.18632/oncotarget.16752

Ejemplares similares